Indaptus stockholders approve amended 2021 stock plan at annual meeting

Indaptus Therapeutics, Inc.

Three Class III directors elected: Roger J. Pomerantz, Michael J. Newman, Jeffrey A. Meckler.
Ratification of Haskell & White LLP as independent auditor for fiscal 2024 approved (3,805,215 FOR vs 469,553 AGAINST).
Amendment to 2021 Stock Incentive Plan approved, increasing shares available and extending evergreen provision (1,881,194 FOR vs 501,555 AGAINST).
Quorum of 4,277,437 shares (50.09% of outstanding) present at June 6, 2024 meeting.
Plan amendment restatement effective June 6, 2024; full text filed as Exhibit 10.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.